JenaValve Technology is developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease.
JenaValve Technology develops and manufactures transapical transcatheter aortic valve implantation systems. JenaValve Technology serves customers worldwide.
JenaValve Technology was founded in 2006 by Hans-Reiner Figulla and Markus Ferrari. The company is headquartered in Irvine, California, with offices in Germany and United Kingdom.
The JenaValve™ Pericardial Transcatheter Aortic Valve Replacement (TAVR) System is designed to treat symptomatic, severe aortic stenosis and symptomatic, severe aortic regurgitation using a single valve prosthesis construct. Unlike other TAVR designs, this technology does not require rapid pacing.
The unique JenaValve technology comprises a porcine pericardial trileaflet valve mounted on a low profile nitinol self-expanding frame with integral locators that engage with the native valve cusps and leaflets.
JenaValve Technology is backed by Bain Capital Life Sciences, Andera Partners, Gimv, Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and others. The company raised $50M in an equity financing on Feb 05, 2020. This brings JenaValve's total funding to $191.1M to date.